Nikhil C. Munshi, MD

Adjunct Associate Professor, Boston University Chobanian & Avedisian School of Medicine

Biography

Dr. Nikhil Munshi received his medical degree from Maharaja Sayajirao University, followed by an internship and residency in internal medicine at Shri Sayaji General Hospital and Maharaja University in India. He then completed an oncology fellowship at Johns Hopkins Ocology Center, and an hematology/oncology fellowhip at Indiana University Medical Center. Dr. Munshi is currently professor of medicine in the Department of Medicine at Harvard Medical School, as well as an attending physician at VA Boston Healthcare System and Dana-Farber Cancer Institute.

A diplomate of American Board of Internal Medicine, Dr. Munshi is also on the Board of Directors of the International Myeloma Society. He is a member of numerous professional associations including the Indian Medical Association, Physician’s Association of India, Indian Association of Clinical Oncology, American Medical Association, American Society of Clinical Oncology, and the American Society of Hematology, among others. In addition, he is on the editorial board of Clinical Lymphoma and Myeloma and Personalized Medicine in Oncology and is an ad hoc reviewer for numerous professional journals.

Dr. Munshi’s current laboratory research and clinical activities specialize in plasma cell disorders with a focus on understanding oncogenomic changes in myeloma and developing a translational research programs in myeloma. He has also established a Myeloma Initiative at Veterans Administration Hospitals, a comprehensive program bringing together, for the first time, all major VA hospitals across the country to focus on cutting-edge joint clinical studies.

Publications

  • Published 8/26/2025

    Frenking JH, Zhou X, Rejeski K, Wagner V, Costello P, Hielscher T, Gatti L, Kauer J, Nadeem O, Mai EK, Michel CS, Friedrich MJ, Sedloev D, Weinhold N, Goldschmidt H, Herfarth K, Schmitt A, Hundemer M, Schmitt M, Müller-Tidow C, Topp M, Einsele H, Dreger P, Munshi NC, Sperling AS, Rasche L, Sauer S, Raab MS. Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma. Blood Adv. 2025 Aug 26; 9(16):4151-4166. PMID: 40267180.

    Read at: PubMed

  • Published 7/3/2025

    Chakraborty C, Talluri S, Binder M, Morelli E, Mayoral JE, Derebail S, Samur AA, Epstein C, Anderson KC, Shammas M, Samur MK, Fulciniti M, Munshi NC. Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma. Blood. 2025 Jul 03; 146(1):104-114. PMID: 40090008.

    Read at: PubMed

  • Published 5/22/2025

    Morelli E, Aktas Samur A, Maisano D, Gao C, Favasuli VK, Papaioannou D, De Nola G, Henninger JE, Liu N, Turi M, Folino P, Vreux L, Cumerlato M, Chen L, Aifantis I, Fulciniti M, Anderson KC, Lytton-Jean AK, Gulla A, Young R, Samur MK, Munshi NC. CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs. Blood. 2025 May 22. PMID: 40403231.

    Read at: PubMed

  • Published 5/15/2025

    Morelli E, Ribeiro CF, Rodrigues SD, Gao C, Socciarelli F, Maisano D, Favasuli V, Liu N, Todoerti K, Chakraborty C, Yao Y, Fulciniti M, Samur M, Aktas-Samur A, Amodio N, Turi M, Barello F, Penailillo J, Giallongo C, Romano A, Gulla A, Anderson KC, Inghirami G, Munshi NC, Loda M. Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma. Clin Cancer Res. 2025 May 15; 31(10):1975-1987. PMID: 40053701.

    Read at: PubMed

  • Published 5/15/2025

    Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC. Editor's Note: Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res. 2025 May 15; 31(10):2063. PMID: 40370044.

    Read at: PubMed

View All 622 Publications:   View Full Profile in BUMC

Websites

Education

  • Maharaja Sayajirao University, MD
  • Maharaja Sayajirao University, MBBS

View all profiles